Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) COO Robert J. Perez unloaded 1,003 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $63.68, for a total transaction of $63,871.04. Following the completion of the transaction, the chief operating officer now directly owns 47,325 shares in the company, valued at approximately $3,013,656. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 1.85% on Monday, hitting $64.56. The stock had a trading volume of 646,394 shares. Cubist Pharmaceuticals has a one year low of $58.50 and a one year high of $82.12. The stock has a 50-day moving average of $64.68 and a 200-day moving average of $69.53. The company has a market cap of $4.889 billion and a P/E ratio of 556.05.

Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.71 earnings per share for the current fiscal year.

A number of research firms have recently commented on CBST. Analysts at Zacks downgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $58.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $79.64.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.